Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

US court permits generic version of Teva MS drug a year sooner
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Pharmacology and therapeutic potential of interferons.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Cyclophosphamide
Phase 3 Study of RPC1063 in Relapsing MS
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Federation of Clinical Immunology Societies 2012
Pregnancy outcomes in patients exposed to interferon beta-1b.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Genzyme’s Lemtrada Approved by the FDA

Pages